Last reviewed · How we verify

NCT04012320: Bisphosphonate

Efficacy and Safety on the Use of Bisphosphonates in Paediatrics

Completed Last updated 9 July 2019
What this trial tests

trial testing No intervention, observational study in Bone Fragile in 99 participants. Completed in 31 December 2018.

Timeline
31 October 2018
Primary endpoint
31 December 2018
31 December 2018

Quick facts

Lead sponsorCentre Hospitalier Universitaire de Nīmes
StatusCompleted
Study typeOBSERVATIONAL
Enrollment99
Start date31 October 2018
Primary completion31 December 2018
Estimated completion31 December 2018
Sites1 location across France

Drugs / interventions tested

Conditions studied

Sponsor

Centre Hospitalier Universitaire de Nīmes

Who can join

Under 18, any sex, with Bone Fragile or Bisphosphonate-Associated Osteonecrosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The investigators suppose that the impact of bisphosphonate therapy is beneficial on the bone during the growth period with few adverse events.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Outcomes of Clinical Trials on Osteonecrosis of the Jaw.
    Wu BW, Lee KC, Halepas S, Karlis V. · · 2021 · PMID 34660159 · DOI 10.7759/cureus.17984

Verify or expand the search:

Other trials of No intervention, observational study

Trials testing the same drug.

Other Centre Hospitalier Universitaire de Nīmes trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04012320.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing